Matheus Vieira

ORCID: 0000-0003-4588-0403
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • COVID-19 Clinical Research Studies
  • Vasculitis and related conditions
  • Systemic Lupus Erythematosus Research
  • Long-Term Effects of COVID-19
  • Ocular Diseases and Behçet’s Syndrome
  • SARS-CoV-2 and COVID-19 Research
  • Geometric Analysis and Curvature Flows
  • Geometry and complex manifolds
  • Chronic Lymphocytic Leukemia Research
  • Autoimmune and Inflammatory Disorders Research
  • Science and Education Research
  • Inflammasome and immune disorders
  • Hepatitis C virus research
  • Retinal and Optic Conditions
  • Peripheral Neuropathies and Disorders
  • Immunodeficiency and Autoimmune Disorders
  • Dyeing and Modifying Textile Fibers
  • Otitis Media and Relapsing Polychondritis
  • Advanced Differential Geometry Research
  • Blood groups and transfusion
  • Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Atherosclerosis and Cardiovascular Diseases
  • Sarcoidosis and Beryllium Toxicity Research
  • Complement system in diseases
  • Heparin-Induced Thrombocytopenia and Thrombosis

Sorbonne Université
2020-2025

Assistance Publique – Hôpitaux de Paris
2020-2025

Centre de Référence des Maladies Autoinflammatoires et des Amyloses
2020-2025

Inserm
2021-2025

Pitié-Salpêtrière Hospital
2020-2024

Universidade Estadual Paulista (Unesp)
2020-2024

Universidade de São Paulo
2023-2024

Universidade Federal do Piauí
2024

Centre National de la Recherche Scientifique
2021-2023

Universidade Federal de São Paulo
2004-2023

Prognostic factors of coronavirus disease 2019 (COVID-19) patients among European population are lacking. Our objective was to identify early prognostic upon admission optimize the management COVID-19 hospitalized in a medical ward. This French single-center prospective cohort study evaluated 152 with positive severe acute respiratory syndrome 2 real-time reverse transcriptase–polymerase chain reaction assay, Internal Medicine and Clinical Immunology Department, at Pitié-Salpêtrière's...

10.1371/journal.pone.0240711 article EN cc-by PLoS ONE 2020-10-19

The COVID-19 pandemic has raised numerous questions among patients with immune-mediated inflammatory diseases regarding potential reciprocal effects of and their underlying disease, immunomodulatory therapy on outcomes related to COVID-19. seroprevalence SARS-CoV-2 factors associated symptomatic in are still unclear. Euro-COVIMID study aimed determine the serological clinical prevalence diseases, as well occurrence impact its management.In this multicentre cross-sectional study, aged 18...

10.1016/s2665-9913(21)00112-0 article EN other-oa The Lancet Rheumatology 2021-04-28

10.1016/j.banm.2024.10.022 article Bulletin de l Académie Nationale de Médecine 2025-01-01

A Prática Avançada de Enfermagem tem ganhado relevância no Brasil, ampliando as competências dos enfermeiros na gestão do cuidado e em intervenções clínicas. Este estudo teve como objetivo identificar principais tendências das práticas avançadas da Obstétrica, conduzidas nas bases PubMed, CINAHL LILACS plus, utilizando a estratégia PICo. Após triagem análise, foram incluídos quatro artigos publicados entre 2017 2021. Os resultados revelaram que prática avançada enfermagem oferece benefícios...

10.55905/revconv.18n.4-192 article PT Contribuciones a las Ciencias Sociales 2025-04-14

10.1016/j.vasdi.2025.01.101 article FR Vascular Diseases 2025-03-01

INTRODUCTION: Direct-acting antiviral agents (DAAs) have modified the management of chronic hepatitis C virus (HCV) infection, including HCV-related cryoglobulinemic vasculitis (CryoVas). However, patients might experience relapse, and no reliable predictors CryoVas relapse after sustained virologic response (SVR) been established. We aimed to describe HCV-CryoVas rates factors associated with it. METHODS: An international multicenter cohort where from Egypt, France, Italy treated DAA were...

10.14309/ajg.0000000000001667 article EN The American Journal of Gastroenterology 2022-01-29

Type I cryoglobulinemia (CG) accounts for 10%-15% of all cryoglobulinemias and are exclusively seen in clonal proliferative hematologic conditions. In this multicenter nationwide cohort study, we analyzed the prognosis long-term outcomes 168 patients with type CG (93 (55.4%) IgM 75 [44.6%] IgG). Five- 10-year event-free survivals (EFS) were 26.5% (95% CI 18.2%-38.4%) 20.8% 13.1%-33.1%), respectively. multivariable analysis, factors associated poorer EFS renal involvement (HR: 2.42, 95%...

10.1002/ajh.26944 article EN American Journal of Hematology 2023-05-04

BackgroundCyclophosphamide and infliximab are recommended as induction therapies for severe Behçet's syndrome. Whether is safer more effective than cyclophosphamide in treating syndrome not known.MethodsIn this phase 2, Bayesian, multicenter randomized controlled trial, we assigned patients fulfilling the International Study Group's criteria who had major vascular or central nervous system involvement to receive either intravenous (5 mg/kg at weeks 0, 6, 12, 18) (0.7 g/m2 intravenously 4, 8,...

10.1056/evidoa2300354 article EN NEJM Evidence 2024-10-22

Abstract Background Prognostic factors of coronavirus disease 2019 (COVID-19) patients among European population are lacking. Our objective was to identify early prognostic upon admission optimize the management COVID-19 hospitalized in a medical ward. Methods French single-center prospective cohort study 152 with positive Severe acute respiratory syndrome 2 (SARS-Cov2) real-time reverse transcriptase-polymerase chain reaction (RT-PCR) assay, Multivariable models and simplified scoring...

10.1101/2020.05.04.20090118 preprint EN medRxiv (Cold Spring Harbor Laboratory) 2020-05-08

Mucocutaneous and joint disorders are the most common manifestations in Behçet's syndrome (BS) frequently clustered so-called minor forms of BS. There remains a need for safe effective treatment lesions We report long-term safety effectiveness apremilast refractory mucocutaneous French nationwide multicenter study including 50 BS patients with either active and/or resistant to colchicine DMARDs. Patients received 30 mg twice day. Primary endpoint was proportion complete response (CR)...

10.3389/fimmu.2020.626792 article EN cc-by Frontiers in Immunology 2021-02-04

In this large multicentre study, we compared the effectiveness and safety of tocilizumab intravenous versus subcutaneous (SC) in 109 Takayasu arteritis (TAK) patients.We conducted a retrospective study referral centres from France, Italy, Spain, Armenia, Israel, Japan, Tunisia Russia regarding biological-targeted therapies TAK, since January 2017 to September 2019.A total TAK patients received at least 3 months therapy were included study. Among them, 91 18 SC tocilizumab, respectively. A...

10.1136/rmdopen-2022-002830 article EN cc-by-nc RMD Open 2023-06-01

Objective Few population-based studies for Takayasu arteritis (TAK) have been performed, and Latin America prevalence/incidence data are unavailable. We aimed to understand TAK epidemiology in Rio de Janeiro City 2020 (i.e., 6,747,815 inhabitants). Methods This was a cross-sectional fieldwork study where physicians who regularly followed patients public or private practices from were invited complete REDCap survey. Patients should fulfill internationally accepted criteria be living the city....

10.1097/rhu.0000000000001964 article EN JCR Journal of Clinical Rheumatology 2023-04-17

We report an original case of reversible antiphospholipid syndrome (APS) due to minocycline in a young male patient who experienced recurrent strokes while taking minocycline. He started therapy (50 mg twice daily) at 15 years old for acne. After three treatment, the lateral medullary syndrome. was treated with aspirin continued. Eighteen months later, complained about horizontal binocular diplopia. MRI revealed infarct oculomotor nerve nucleus. Laboratory investigations high titers...

10.1177/0961203317712463 article EN Lupus 2017-06-07
Coming Soon ...